New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 1 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 2 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 500mg - powder for injection - 500 mg - active: ceftazidime pentahydrate 500mg excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg;  ; vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg;   - powder for inhalation - 62.5mcg/25mcg - active: umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg   vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg   excipient: lactose monohydrate magnesium stearate - long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 720 eu/ml;  ; hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis a vaccine 720 eu/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - active: hepatitis a vaccine 720 eu/ml   hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids formaldehyde neomycin sulfate phenoxyethanol polysorbate 20 sodium chloride water for injection active: hepatitis a vaccine 720 eu/ml hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids dibasic sodium phosphate monohydrate formaldehyde monobasic sodium phosphate dihydrate neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - twinrix is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults. twinrix is also indicated for active immunisation against hepatitis a and hepatitis b virus infection in infants, children and adolescents from 1 year up to and including 15 years of age at risk of, or who wish to be protected against, both infections.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 720 eu/ml;  ; hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis a vaccine 720 eu/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - active: hepatitis a vaccine 720 eu/ml   hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids formaldehyde neomycin sulfate phenoxyethanol polysorbate 20 sodium chloride water for injection active: hepatitis a vaccine 720 eu/ml hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids dibasic sodium phosphate monohydrate formaldehyde monobasic sodium phosphate dihydrate neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - twinrix junior is indicated for active immunisation against hepatitis a and hepatitis b virus infection in infants, children and adolescents from 1 year up to and including 15 years of age at risk of, or who wish to be protected against, both infections.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) - powder with diluent for oral suspension - 1e+006 ccid50 - active: rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) excipient: amino acids dextran 40 dulbecco's modified eagle medium sorbitol sucrose calcium carbonate water for injection xanthan gum - rotarix is indicated for the prevention of rotavirus gastroenteritis

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) - oral suspension - 1e+006 ccid50 - active: live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) excipient: di-sodium adipate dulbecco's modified eagle medium sucrose water for injection - rotarix is indicated for the prevention of rotavirus gastroenteritis

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - mepolizumab 144mg ((100 mg/ml after reconstitution with 1.2 ml of wfi, delivers 1 ml)) - powder for injection - 100 mg/ml - active: mepolizumab 144mg ((100 mg/ml after reconstitution with 1.2 ml of wfi, delivers 1 ml)) excipient: dibasic sodium phosphate heptahydrate hydrochloric acid polysorbate 80 sucrose - nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 60 iu/ml; pertactin 16 µg/ml; pertussis filamentous haemagglutinin 50 µg/ml; pertussis toxoid, adsorbed 50 µg/ml; polio virus type 1 80 dagu/ml; polio virus type 2 16 dagu/ml; polio virus type 3 64 dagu/ml; tetanus toxoid, adsorbed 80 iu/ml - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 60 iu/ml pertactin 16 µg/ml pertussis filamentous haemagglutinin 50 µg/ml pertussis toxoid, adsorbed 50 µg/ml polio virus type 1 80 dagu/ml polio virus type 2 16 dagu/ml polio virus type 3 64 dagu/ml tetanus toxoid, adsorbed 80 iu/ml excipient: aluminium hydroxide neomycin sulfate polymyxin b sulfate sodium chloride water for injection - infanrix®-ipv is indicated for active primary immunisation against diphtheria, tetanus, pertussis, and poliomyelitis. infanrix®-ipv is also indicated as a booster dose for children who have previously been immunised with dtp and polio antigens.